Journal Home
Search for

Volume 65, Issue 3, Pages 478-482 (2005)


View previous. 7 of 41 View next.

Lactoferrin-enhanced anoikis: A defense against neonatal necrotizing enterocolitis

Michael P. ShermanaCorresponding Author Informationemail address, Karel Petrakb

Received 29 March 2005; accepted 4 April 2005. published online 14 June 2005.

Summary 

Enteral nutrition with human milk lowers the incidence of necrotizing enterocolitis in preterm human infants. Lactoferrin, the major whey protein in human milk, has many functions related to host defense against bacterial infection. Here, we hypothesize that lactoferrin also helps terminate bacterial invasion of enterocytes via a detachment-induced apoptosis called anoikis. Death of infected epithelia by anoikis prevents local spread of bacterial pathogens because the bacteria are trapped within the cell. Such infected, apoptotic and sloughed epithelia also cannot infect the lower gastrointestinal tract, and the epithelia exit the body in the stool. Currently, anoikis is a phenomenon related to the renewal of enterocytes, and it is not recognized as an anti-bacterial host defense. We suggest that anoikis of infected enterocytes is a process in which lactoferrin plays an important role. In a pilot study in which neonatal rats were pre-treated with intra-gastric recombinant human lactoferrin, we found evidence of epithelia with anoikis in ileal fluid after enteric infection. This finding was rarely seen in infected neonatal rats without pre-treatment with lactoferrin. Quantitative analysis of intestinal lavage specimens and quantitative stereology of apoptotic epithelia in this model will be required to verify the theory. We propose that oral use of recombinant human lactoferrin might have these hypothesized and other anti-bacterial effects in preterm infants, and hence, this protein might prevent necrotizing enterocolitis in preterm infants who cannot take human milk.

a Division of Neonatology, School of Medicine, University of California, Surge I, Suite 1121, Davis, CA 95616, USA

b Agennix, Inc., 8 Greenway Plaza, Suite 910, Houston, TX 77046, USA

Corresponding Author InformationTel.: +1 217 529 6721; fax: +1 530 752 6215.

PII: S0306-9877(05)00197-0

doi:10.1016/j.mehy.2005.04.010


View previous. 7 of 41 View next.